2008 Press Releases Communiqués de presse

October 15, 2008 15 October, 2008

Jeffrey Bacha Appointed to Sernova Board of Directors - Grant of Stock Options

August 13, 2008 13 August, 2008

Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News

July 30, 2008 30 July, 2008

Appointment of New Officers

May 6, 2008 6 May, 2008

Sernova Concludes Successful Pre-IND Meeting with FDA

April 16, 2008 16 April, 2008

Sernova Corp. Annual Meeting

March 25, 2008 25 March, 2008

Islet Cell Pioneer Appointed to Help Advance Sertolin Diabetes Therapy

March 18, 2008 18 March, 2008

Sernova to Take Its First Regulatory Step Towards Clinical Trials - Granted Formal Pre-IND Meeting with FDA

March 17, 2008 17 March, 2008

Sernova Corp. Grants Stock Options

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 15, 2008 15 October, 2008

Jeffrey Bacha Appointed to Sernova Board of Directors - Grant of Stock Options


London, Ontario --October 15, 2008 - Sernova Corp. (TSX-V: SVA)

Dr. George Adams, Chairman of the Board of Directors of Sernova Corp., is pleased to announce the appointment of Jeffrey Bacha to the Board of Directors. Mr. Bacha brings 15 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States and Europe. "Jeffrey will add considerable depth and expertise to the Sernova Board", said Dr. Adams, "and will play a key role in Sernova commercializing its treatment for insulin- dependent diabetes."

Mr. Bacha is currently Executive Vice President, Corporate Affairs and Chief Operating Officer of Clera Inc., a company developing new medicines to treat serious CNS diseases, including schizophrenia, depression and Parkinson's disease. From 2002 through 2005, Mr. Bacha launched Inimex Pharmaceuticals as President and Founding Chief Executive Officer, securing more than $35 million in grant and venture capital financing. Inimex recently completed a $22 million Series B financing and is ready to advance its first drug candidate into human clinical trials in the 2008 - 2009 timeframe. Prior to 2002, Jeffrey served as Vice President, Corporate Development of Inflazyme Pharmaceuticals Ltd., was a founding Board member of Urigen Holdings Inc., and was founding CFO and Vice President, Corporate Development of XBiotech Inc. Mr. Bacha was also Senior Manager and Director of KPMG's U.S. Health Ventures and Life Sciences Corporate Finance Group in San Francisco.

Originally from California, Mr. Bacha holds a B.Sc. in Biophysics from the University of California and an M.B.A. from the Goizueta Business School at Emory University. Both Inimex and Inflazyme were recognized as "Top 10 Life Sciences Investment Opportunities" in Canada during every year of Mr. Bacha's tenure at those companies. Mr. Bacha has received personal honours as one of the "Top 40 Under 40" business persons in British Columbia, and in 2004 was nominated for the Ernst & Young Entrepreneur of the Year Award.

Sernova also announces the granting of incentive stock options to a director and an officer to purchase up to an aggregate of 100,000 common shares at $0.12 per share for a period of 5 years expiring October 15, 2013.

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertoli cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Craig Gauld, Executive Vice President Tel: (888) 318-7062; (519) 858-5126 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 13, 2008 13 August, 2008

Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News


London, Ontario --August 13, 2008 - Sernova Corp. (TSX-V: SVA)

Sernova Corp.'s Sertolin technology is being highlighted at the International Congress of The Transplantation Society (TTS) in Sydney, Australia this week, and was also featured on CTV's National News on Sunday night, with the message that Canadian innovation may be changing the face of diabetes forever.

"Our cell replacement technology, Sertolin, could free insulin dependent (Type 1) diabetics from insulin injections forever," said Dr. David White, Principal Researcher for Sernova Corp. and presenter at the TTS international congress. "We are working to change what it means to be a diabetic, and we are doing it today."

Dr. White's presentation at thecongress, and the CTV National News media coverage, both describe the development of Sernova'sinsulin replacement cellular therapy called Sertolin. A small medical device containing two types of mature porcine (pig) cells (islet and Sertoli cells) is implanted just beneath the skin of a Type 1 diabetic's abdomen.The cells produce insulin that is compatible with human insulin, thus reducing or eliminating the need for constant insulin injections. The Sertoli cells protect the islets from attack by the immune system, eliminating the need for anti-rejection drugs that cause significant side effects.

"Sertolin is so important in the fight against diabetes," said Dr. White. "This is not just about insulin; it's about quality of life and reducing the life threatening complications that come along with this disease. Sertolin will make life easier for diabetics. I am proud to see Sernova's important work highlighted at the International Congress of The Transplantation Society in Sydney and featured on the CTV National News."

"Dr. White's invitation to present our Sertolin data in Sydney shows the high degree of scientific interest in our work in the international scientific community,"commented Justin Leushner, President and CEO of Sernova Corp. "We are excited to share our story."

To watch the CTV National News piece --please click on link below http://watch.ctv.ca/news/latest/controversial- research/#clip72928

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Craig Gauld, Executive Vice President Tel: (519) 858-5126 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 30, 2008 30 July, 2008

Appointment of New Officers


London, Ontario - July 30, 2008 - Sernova Corp. (TSX-V: SVA)

Sernova is pleased to announce that Craig Gauld has been appointed as Executive Vice President. Mr. Gauld holds science and law degrees from the University of Western Ontario, and brings over 20 years experience in management, law, finance and administration in the international biotechnology and technology sectors. Mr. Gauld will be replacing current Executive Vice President Phil Morehouse who has resigned effective May 15, 2008 to pursue private business opportunities.

Sernova is also pleased to announce the appointment of William G. Smethurst as Chief Financial Officer. Mr. Smethurst is a Chartered Accountant with over 25 years experience, starting at Coopers & Lybrand and progressing into senior management positions in the finance, leasing, energy and biotechnology sectors. His expertise includes finance, operations and business development in the private and public sectors. Mr. Smethurst is replacing Patrick Groening who resigned as CFO as of June 30, 2008.

Justin Leushner, President of Sernova, said: "These two appointments have allowed us to consolidate the management of the company in London, Ontario where our research laboratories are located. Craig and Bill bring many years of international biotechnology experience which will be important as we advance to clinical trials of our lead Sertolin product for diabetes."

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Tel: (519) 858-5126 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 06, 2008 6 May, 2008

Sernova Concludes Successful Pre-IND Meeting with FDA


London, Ontario - May 6, 2008 - Sernova Corp. (TSX-V: SVA)

Sernova Corp. today announced the successful conclusion of a meeting with the U.S. Food and Drug Administration (FDA) that established definitive requirements for the filing of an Investigational New Drug (IND) application, which is required to advance Sertolin into human Clinical Trials. Sertolin is the Corporation's proprietary technology for treating insulin-dependent diabetes. After review of Sernova's pre-clinical testing data in rodents to date, the FDA specified that the next stage will be a pivotal pre- clinical trial consisting of a single large animal trial with clear endpoints, leading to a Phase I/II human Clinical Trial. The pivotal pre-clinical trial is expected to take about 18 months to complete and will assess the long- term safety and durable activity of Sertolin.

Justin Leushner, President of Sernova, noted "This key development reflects the interest of the FDA in diabetes therapies, and creates a definitive path for Sernova to initiate "first in man" Clinical Trials to advance our unique technology through the regulatory process required for human use."

The FDA meetings clarified the details of the development path for Sernova's xenotransplantation approach to treat diabetes, which incorporates co-transplantation of insulin- producing porcine islet cells and Sertoli cells within a small subcutaneous medical device. "Sernova appreciates the positive instruction and interactions we received in our pre-IND meeting with the FDA," said Dr. David White, Lead Scientist for Sernova. "Their clear advice and direction will greatly assist our future IND application as we look toward the crucial Clinical Trials in humans."

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: TEL: (888) 318-7062 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 16, 2008 16 April, 2008

Sernova Corp. Annual Meeting


Sernova Corp. (the "Company") will be holding its Annual Meeting of Shareholders on Friday April 18, 2008 at 3:00 p.m. in the Calgary Petroleum Club, Calgary, Alberta. Please refer to the Notice of Meeting and Management Proxy Circular filed on www.sedar.com for further information.

The Company is revising the disclosure in its news release of March 17, 2008 pertaining to the grant of incentive stock options to directors, officers and employees as the original number of options was disclosed as 375,000 whereas the grant is for the purchase of up to 325,000 common shares at $0.30 per share for a period of 5 years expiring March 13, 2013.

About Sernova Corp.

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

ON BEHALF OF THE BOARD "Justin Leushner" Justin Leushner, President and CEO

For further information contact:

Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 25, 2008 25 March, 2008

Islet Cell Pioneer Appointed to Help Advance Sertolin Diabetes Therapy


Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce that world class, pancreatic islet transplant expert, Dr. Shinichi Matsumoto, Director of the Baylor All Saints Islet Cell Laboratory at the Baylor Research Institute in Fort Worth Texas, has accepted an appointment to Sernova's Scientific Advisory Board (SAB). Dr. Matsumoto is a pioneer in human islet transplantation to treat diabetics. He has many notable accomplishments in the field of islet transplantation, which will assist Sernova in pursuing its clinical regulatory path going forward. His research has resulted in numerous scientific publications on islet isolation, preparation and transplantation. "With his knowledge of the intricacies of islet biology and islet transplants, Dr. Matsumoto is a key addition to our SAB and Sernova's diabetes therapy research," commented Dr. David White, Sernova's Principal Researcher. "His expertise in islets complements well that of the other SAB members who are experts in diabetes, immunology, and Sertoli cells."

About Dr. Matsumoto Dr. Matsumoto is currently the Director of the Baylor All Saints Islet Cell Laboratory, and the Islet Cell Transplantation Laboratory at the Baylor Research Institute. Dr. Matsumoto graduated from medical school in 1988 and received his postgraduate training in 1996 from Kobe University School of Medicine in Kobe, Japan. He is board certified in surgery and gastroenterological surgery. He joined the medical staff of Kobe University Hospital in 1996. From 1997 to 2002, Matsumoto studied at islet transplant centers in Minneapolis and Seattle. Dr. Matsumoto joined Northwest Tissue Center (Seattle) in 2000, as senior research scientist in Human Islet Transplantation and consultant to the Human Islet Processing Facility. Just prior to joining Baylor he served as assistant professor at Kyoto University Hospital Transplantation Unit and as Director of the Diabetes Research Institute in Kyoto.

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin- dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 18, 2008 18 March, 2008

Sernova to Take Its First Regulatory Step Towards Clinical Trials - Granted Formal Pre-IND Meeting with FDA


Kelowna, B.C. - Sernova Corp. (TSX-V: SVA) is pleased to announce that the company will be meeting with the United States Food and Drug Administration (FDA) on April 25, 2008 regarding Sertolin, the company's investigational cellular therapy being developed for diabetes treatment. This formal pre- Investigational New Drug (IND) meeting is Sernova's first step in seeking IND approval to initiate clinical trials in humans. The FDA meeting will provide Sernova with the opportunity to present its experimental data on Sertolin, obtain feedback on its pre-clinical data package, and receive the FDA's perspective on its proposed clinical strategy.

Sernova CEO Justin Leushner stated "With our dedicated work and focus on the Sertolin product, we have put ourselves in a good position to move another step towards commercialization by beginning discussions with FDA for launching Sertolin into human clinical trials. We expect to work closely with the FDA in a collaborative effort to ensure optimal opportunity for success for Sertolin."

With the completion of its large-scale animal efficacy study on Sertolin, announced on December 10, 2007, Sernova is now focusing on completing the scale-up and design of the chamber for human application, finalizing arrangements to secure porcine cells for human trials, and continuing to monitor the long-term animal studies.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertoli cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner" Justin Leushner, President

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 17, 2008 17 March, 2008

Sernova Corp. Grants Stock Options


Sernova Corp. (the "Company") has granted incentive stock options to directors, officers and employees to purchase up to 375,000 common shares at $0.30 per share for a period of 5 years expiring March 14, 2013.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President and CEO

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.